Supply Chain Intelligence

Nurix Therapeutics, Inc. Supply Chain

NRIX supply chain intelligence for Nurix Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

NRIX ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

5Suppliers
11Customers
3Debt Items
20Related Chains

Nurix Therapeutics, Inc. Suppliers

TickerNameConfidenceEvidence
PIPER-SANDLER-CO PIPER-SANDLER-CO 90% the Company may offer and sell through Piper Sandler, as sales agent, $413.65 million of shares of the Company’s common stock
GILD Gilead Sciences, Inc. 72% g Administration (FDA), the European Medicines Agency (EMA) or other regulatory authorities to perform trials in addition to those we currently expect, or if there are any delays in establishing appr…
GILD Gilead Sciences, Inc. 72% Reciprocal relationship from GILD graph: Reciprocal relationship from NRIX graph: Reciprocal relationship from GILD graph: Reciprocal relationship from NRIX graph: Reciprocal relationship from GILD g…
SNYNF Sanofi 72% , have an exercise price of $0.001 and may be exercised at any time after the date of issuance. A holder of the pre-funded warrants may not exercise the warrant if the holder, together with its affil…
SNYNF Sanofi 72% Reciprocal relationship from SNYNF graph: Reciprocal relationship from NRIX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from NRIX graph: , have an exercise price of $0.00…

Nurix Therapeutics, Inc. Customers

TickerNameConfidenceEvidence
F-HOFFMANN-LA-ROCHE-LTD F-HOFFMANN-LA-ROCHE-LTD 92% Nurix will grant Roche an exclusive worldwide license, including with respect to Nurix and its affiliates, under certain Nurix intellectual property rights
GENENTECH-INC GENENTECH-INC 92% Nurix will grant Roche an exclusive worldwide license, including with respect to Nurix and its affiliates, under certain Nurix intellectual property rights
GILEAD GILEAD 92% Under the Gilead Agreement, Gilead has the option to license drug candidates directed to up to five targets resulting from the collaboration and is responsible for the clinical development and commer…
SANOFI SANOFI 90% In December 2019, we entered into a strategic collaboration with Genzyme Corporation, a subsidiary of Sanofi, which became effective in January 2020
PFE Pfizer Inc. 85% Reciprocal relationship from PFE graph: Reciprocal relationship from NRIX graph: Reciprocal relationship from PFE graph: Reciprocal relationship from NRIX graph: In our partnership with Pfizer, which…
PFE Pfizer Inc. 85% In our partnership with Pfizer, which was announced in September 2023 under an agreement with Seagen, Inc., we have achieved two preclinical milestones to date, qualifying for $10.0 million in milest…
GILD Gilead Sciences, Inc. 72% g Administration (FDA), the European Medicines Agency (EMA) or other regulatory authorities to perform trials in addition to those we currently expect, or if there are any delays in establishing appr…
GILD Gilead Sciences, Inc. 72% Reciprocal relationship from GILD graph: Reciprocal relationship from NRIX graph: g Administration (FDA), the European Medicines Agency (EMA) or other regulatory authorities to perform trials in addi…
KYMR Kymera Therapeutics, Inc. 72% Reciprocal relationship from KYMR graph: hese manufacturers on a purchase order basis and do not have long-term supply arrangements in place. Should any of these manufacturers become unavailable to u…
SNYNF Sanofi 72% Reciprocal relationship from SNYNF graph: Reciprocal relationship from NRIX graph: , have an exercise price of $0.001 and may be exercised at any time after the date of issuance. A holder of the pre-…
SNYNF Sanofi 72% , have an exercise price of $0.001 and may be exercised at any time after the date of issuance. A holder of the pre-funded warrants may not exercise the warrant if the holder, together with its affil…

Nurix Therapeutics, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
NRIX-DEBT-11362 Xbrl Convertible 90% xbrl convertible detail from xbrl 2020-11-30.
NRIX-DEBT Debt stack $58.7M 90% Market cache reports total debt of $58.7M.
NRIX-DEBT-11361 Warrants outstanding: 94759000 90% xbrl warrant detail from xbrl 2022-11-30.

Nurix Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Nurix Therapeutics, Inc..

Nurix Therapeutics, Inc. Ownership

HolderNameConfidenceEvidence
NRIX-OWNER-MORGAN-STANLEY MORGAN STANLEY 90% 13F overlay lists MORGAN STANLEY as top holder; 198 tracked holders.

Nurix Therapeutics, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
DBVTF DBV TECHNOLOGIES 100.00 2
EDIT Editas Medicine, Inc. 100.00 2
CHRS Coherus Oncology, Inc. 100.00 2
BLRX BioLineRx Ltd. 100.00 2
CYTOF Altamira Therapeutics Ltd. 100.00 2
WHWK Whitehawk Therapeutics, Inc. 100.00 2
AZN AstraZeneca PLC 100.00 2
ANRO Alto Neuroscience, Inc. 100.00 2
ALXO ALX Oncology Holdings Inc. 100.00 2
AVIR Atea Pharmaceuticals, Inc. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
CYTK Cytokinetics, Incorporated 100.00 2
CTMX CytomX Therapeutics, Inc. 100.00 2
CBIO Crescent Biopharma, Inc. 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
BPTH Bio-Path Holdings, Inc. 100.00 2
CCCC C4 Therapeutics, Inc. 100.00 1 ['spend']
CCEP Coca-Cola Europacific Partners PLC 100.00 2
DSGN Design Therapeutics, Inc. 100.00 2
FULC Fulcrum Therapeutics, Inc. 100.00 2
View NRIX supply chain intel →

Explore the full interactive supply chain map for Nurix Therapeutics, Inc..

Open NRIX supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map